Related Experiment Video
Updated: Jul 28, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Neuroprotective effects of caffeine, erythropoietin, magnesium sulfate, and thyroxine in preterm infants: a network
Yuqian Wang1, Shanshan Wang1, Haiping Dou1
1Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, China.
Insights
Caffeine demonstrates the most promise in reducing neurodevelopmental impairment and cerebral palsy in premature infants. This network meta-analysis suggests caffeine may be the most effective neuroprotective drug, though further trials are needed for validation.
Area of Science:
- Neonatal Neurology
- Pharmacology
- Evidence Synthesis
Background:
- Premature infants face significant risks of adverse neurodevelopmental outcomes, including cerebral palsy.
- Neuroprotective drugs offer potential to mitigate these neurological deficits in preterm neonates.
- A comparative analysis of common neuroprotective agents is crucial for optimizing infant care.
Purpose of the Study:
- To conduct a network meta-analysis comparing the efficacy of four common neuroprotective drugs.
- To evaluate the impact of erythropoietin, magnesium sulfate, caffeine, and thyroxine on neurodevelopmental outcomes in preterm infants.
- To rank the neuroprotective potential of these drugs based on synthesized evidence.
Main Methods:
- A systematic search of Cochrane Library, PubMed, and EMBASE databases was performed up to March 2024.
- Eligible randomized clinical trials were analyzed, focusing on neurodevelopmental impairment (NDI) or death as the primary outcome.
- Surface Under the Cumulative Ranking Curve (SUCRA) was utilized to rank drug efficacy.
Main Results:
- Caffeine significantly reduced the risk of NDI (RR 0.43) and cerebral palsy (RR 0.55) in premature infants.
- Magnesium sulfate also showed a protective effect against cerebral palsy (RR 0.66).
- SUCRA values indicated caffeine as potentially the most effective neuroprotective agent (NDI: 87.9%, cerebral palsy: 91.2%).
Conclusions:
- Caffeine demonstrated significant neuroprotective effects, reducing both NDI and cerebral palsy risks.
- Magnesium sulfate showed promise in preventing cerebral palsy, particularly when administered during pregnancy.
- While caffeine appears most beneficial, findings are preliminary and require validation through additional clinical trials.
Background:
Premature infants are prone to having adverse neurodevelopmental outcomes such as cerebral palsy. Some neuroprotective drugs can improve adverse neurological outcomes in premature infants. A network meta-analysis was conducted to compare the effects of four common neuroprotective drugs on neurodevelopmental outcomes in preterm infants.
Methods:
To identify eligible randomized clinical trials, three databases (Cochrane Library, PubMed, and EMBASE) were searched from the inception date through March 2024. Neuroprotective drugs included erythropoietin, magnesium sulfate, caffeine, and thyroxine. The primary outcome was whether neurodevelopmental impairment (NDI) or death occurred. Studies that met the eligibility criteria were assessed, and data were extracted. The surface under the cumulative ranking curve (SUCRA) was computed to evaluate and rank the neuroprotective efficacy of various drugs.
Results:
Caffeine [relative risk (RR) 0.43, 95% confidence interval (CI): 0.22-0.86] showed the most promising effect in reducing the risk of premature infants with NDI. Caffeine (RR 0.55, 95% CI: 0.43-0.70) and magnesium sulfate (RR 0.66, 95% CI: 0.54-0.80) showed promising effects in reducing the risk of premature infants with cerebral palsy. According to the SUCRA value, caffeine (NDI: 87.9%, cerebral palsy: 91.2%) may be the best drug for neurodevelopmental protection in preterm infants.
Conclusions:
The neuroprotective effects of caffeine were observed in the reduction of NDI and cerebral palsy, whereas magnesium sulfate, given to pregnant women at risk of preterm birth, had a protective effect in reducing the risk of cerebral palsy. The analysis of the SUCRA value indicated that caffeine may offer greater benefits compared to other medications in the neuroprotection of premature infants. The findings of this network meta-analysis ought to be regarded as theoretical rather than validated. Additional trials are necessary to validate the existing findings.
